VAKCINA

Those numbers use the price of active pharmaceutical ingredient (API) exported from (mainly) India, and a cost estimation algorithm we developed in earlier research (see https://t.co/ivmgbZOKQs) 2/4 pic.twitter.com/yStEb256TS

— Melissa Barber (@mellabarb) October 1, 2021

This working paper is not yet peer reviewed. Thanks to co-author @dizgotham 4/4

— Melissa Barber (@mellabarb) October 1, 2021

Talason wrote:meni ovaj profit margin deluje čudno

PREMIJERKA Srbije Ana Brnabić izjavila je večeras da će sednica Kriznog štaba najverovatnije biti održana u utorak, a da će glavna tema biti vakcinacija i kako motivisati građane da se imunizuju. (...)
Dodaje da su mnoge države počele da skraćuju period između revakcine i „buster“ doze sa šest na pet meseci, pa će sutra u 14 sati da se sastane i Nacionalno telo za imunizaciju. Jedna od tema Kriznog štaba biće upravo i skraćivanje perioda između druge i treće doze.

Vakcinisani prelaze ulicu na zeleno, nevakcinisani pretrčavaju na crveno

Rukovodilac Centra za anesteziologiju i reanimatologiju UKCS Nebojša Lađević izjavio je danas da su Infektivna klinika i kovid bolnica u Batajnici izuzetno opterećene i da se može reći da se traži mesto više.
Lađević je za RTS rekao da u ovom talasu epidemije ima sve više pacijenata koji zahtevaju mehaničku potporu i da će danas biti održan sastanak kako bi bilo otvoreno šesto odeljenje intenzivne nege u Batajnici sa novih 20 kreveta, čime će se broj kreveta na intenzivnoj nezi povećati na 120.
Istakao je da za ljude koji ne veruju u koronavirus motivacija može da bude to što lekari, profesori Medicinskog fakulteta, koji učestvuju u lečenju, poručuju da je veoma različita klinička slika između onih koji su vakcinisani i onih koji nisu vakcinisani.
„Šansa da dođete u veoma kritično stanje, da završite na respiratoru, ako ste vakcinisani, jeste mala. Možda plastično da predstavimo, to vam je razlika kao da vakcinisani prelazi ulicu na pešačkom, na zeleno svetlo, a nevakcinisani pretrčava na crveno u punom saobraćaju. Tolika vam je razlika u šansi da završite sa teškom kliničkom slikom”, poručio je Lađević, javlja Tanjug.
Naveo je da nema pravila i da svi mogu da obole, ali da je najveći broj pacijenata koji su vitalno ugroženi i imaju tešku kliničku nevakcinisani.
„Imamo tu i pacijente koji su davno vakcinisani, gde imamo jedan proboj imuniteta, te je potrebno obratiti pažnju na revakcinu, na ponovno postizanje nivoa antitela i svakako da ima izuzetno mali broj pacijenata koji su vakcinisani redovnim putem, ali iz bilo kog razloga, bilo zato što su primali neku drugu terapiju, zato što im je imuni sistem takav da nisu odgovorili na vakcinaciju, ali se oni ne nalaze u jedinicama intenzivnog lečenja, nisu na respiratorima, već se jednostavno nalaze pod nekim blažim nadzorom”, kazao je Lađević.
Napomenuo je da je važno da se pridržavamo protivepidemijskih mera, da se vakcinišemo, a ukoliko smo zaraženi, da je najbitnije da se na vreme javimo lekaru.

EU drug regulator (EMA) approves BioNTech-Pfizer booster for people 18+ at least 6 months after 2nd shot.

Also greenlights extra dose of BioNTech-Pfizer & Moderna vaccine for people w/ severely weakened immune systems at least 28 days after 2nd shot.https://t.co/KhxchKjVDx pic.twitter.com/0Ezq8CwkH4

— Michael Knigge (@kniggem) October 4, 2021

AstraZeneca requests U.S. FDA to grant emergency use authorization for its new treatment to prevent COVID-19 https://t.co/6iDUgIthsE pic.twitter.com/mKFTVHWgRp

— Reuters (@Reuters) October 5, 2021

AstraZeneca's monoclonal antibody AZD7442 reduced the risk of developing #Covid19 by 77% compared to placebo in a Phase III study, professor of medicine Hugh Montgomery said during a press conference on Wednesday afternoon.

— Nicole DeFeudis (@Nicole_DeFeudis) September 29, 2021

The study, PROVENT, sought to enroll participants who had comorbidities or conditions that would cause a reduced immune response to vaccination, including those who were excluded from vaccine trials.

— Nicole DeFeudis (@Nicole_DeFeudis) September 29, 2021

After boosters, elderly Israelis who are fully inoculated have just one fiftieth of the chance of COVID death compared to unvaccinated people in the same age bracket.
According to Health Ministry data for the last seven days of September, there were 6.43 daily deaths per 100,000 Israelis aged 60-plus. For older people who were vaccinated three times, the average was 0.13.

Seven months after the second dose, there is no reduction in the efficacy of COVID-19 mRNA vaccines in the general population in Italy, while a slight decline is seen for some specific groups, the National Health Institute (ISS) said on Wednesday. https://t.co/UtasOjZdi4

— Reuters Health (@Reuters_Health) October 7, 2021

The report led by ISS and the health ministry examined data up to Aug. 29 from more than 29 million people who had received two doses of an mRNA vaccine such as those produced by Pfizer and Moderna. It said that in the general population, effectiveness against infection after seven months remained at 89%, while against hospitalisation and death, this time six months after the second dose, it remained at 96% and 99% respectively.
...
In Italy, people are obliged to wear masks indoors and they had been required outdoors before the summer, and stringent behavioural rules have been in place, which may have influenced the results.

The ISS report said that immunocompromised people saw their protection against infection drop from 28 days after the second dose, with the reduction varying widely according to which diseases cause the weakened immune system. In people with co-morbidities but who are not necessarily immunodepressed, the study reported a reduction in protection from infection which declined from 75% 28 days after the second dose to 52% after about seven months.

Efficacy among people over the age of 80 and nursing home residents also decreased slightly but remained above 80%, the ISS said.

Comparing the period in which the Alpha variant was prevalent with that in which the Delta variant was, efficacy against infection fell from 84.8% to 67.1%, while protection against hospitalisation declined much less, from 91.7% to 88.7%.

Broj doza: 6.655.878 – prva doza 3.061.127, druga doza 2.929.468, treća doza 665.283
Državljani RS – prva doza 2.890.804, druga doza 2.777.077, treća doza 661.361
Strani državljani sa boravkom u RS – prva doza 10.423, druga doza 9.530, treća doza 1176
Strani državljani bez boravka u RS – prva doza 159.900, druga doza 142.861, treća doza 2.746
ažurirano 07.10.2021

Broj doza: 6.497.670 – prva doza 3.040.293, druga doza 2.901.882, treća doza 555.495
Državljani RS – prva doza 2.870.854, druga doza 2.750.459, treća doza 552.760
Strani državljani sa boravkom u RS – prva doza 10.281, druga doza 9.399, treća doza 852
Strani državljani bez boravka u RS – prva doza 159.158, druga doza 142.024, treća doza 1.883
ažurirano 30.09.2021